Dr. Erika Hamilton spoke with CURE’s editor-in-chief, Dr. Joshua K. Sabari.

HER2CLIMB-05 trial evaluated Tukysa in combination with Herceptin and Perjeta for HER2-positive metastatic breast cancer, ...

Investigator sought to compare treatment strategies that omit chemotherapy and/or include ribociblib against standard treatment for safety and efficacy.

The HER2CLIMB-05 study assessed the efficacy and safety of adding tucatinib to maintenance therapy with trastuzumab/pertuzumab in patients with HER2+ metastatic breast cancer.

Detailed price information for Alx Oncology Holdings Inc (ALXO-Q) from The Globe and Mail including charting and trades.

Z-endoxifen has demonstrated efficacy in phase 1 and 2 trials, improving progression-free survival and tumor response in ...

Iksuda to present preliminary analysis of oesophageal cancer data from phase 1 study of IKS014 at ASCO Gastrointestinal Cancer Symposium: Newcastle, UK Thursday, January 8, 2026, ...

As of Thursday, January 08, Enliven Therapeutics, Inc.’s ELVN share price has surged by 55.72%, which has investors ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.comNews Commentary – ...

Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 ...

Astellas Pharma U.S., Inc. (Head of US Commercial: Mike Petroutsas, "Astellas") today announced the publication of exploratory ad hoc analyses from the combined Phase 3 SPOTLIGHT (NCT03504397) and ...

Following the transaction, Walters Group directly holds 13,509,973 shares of Zentalis Pharmaceuticals. The biopharmaceutical company, currently valued at $181.3 million, holds more cash than debt on ...